Hepatitis B virus (HBV) infection is a major health concern world wide, and few effective treatments have been developed. It has recently been reported that inhibiting host-cell proteins can prevent viral infection. The human genome may contain more genes required for HBV infection and replication than the viral genome. A systematic approach to find these potential antiviral targets is by host gene expression analysis using DNA microarrays. The aim of this study was to identify and validate novel cellular anti-HBV targets. The Human Whole Genome Bioarray was used to analyze differentially expressed genes in HepG2.2.15 cells and HepG2 cells. Altered gene expression in HepG2.2.15 cells was studied following treatment with the anti-HBV drug, lamivudine. Genes that were differentially expressed during HBV infection and reversed with anti-HBV drugs were validated by semiquantitative reverse transcription-PCR. Bioinformatics analysis revealed ABHD2, EREG, ACVR2B, CDC34, KHDRBS3 and RORA as potential cellular anti-HBV targets. Antisense oligodeoxynucleotides were used to test the antiviral activity of these potential targets. Results strongly suggested that inhibition of ABHD2 or EREG significantly blocked HBV propagation in HepG2.2.15 cells. This study demonstrates that ABHD2 and EREG are essential for HBV propagation and provides strong evidence that these proteins could be used as potential targets for anti-HBV drugs.
Introduction
Hepadnavirus is a small hepatotropic DNA-containing virus that replicates through an RNA intermediate. 1 Human hepatitis B virus (HBV), a member of the hepadnavirus family, is responsible for both acute and chronic liver infection. Chronic HBV infection, which causes liver cirrhosis and hepatocellular carcinoma (HCC), is a major global public health problem. Although an effective vaccine has been available for 20 years, and attempts at universal vaccination are now underway in developed countries, 2 there are an estimated 350 million hepatitis B carriers. Current antiviral therapies for HBV carriers include a-interferon or lamivudine treatment; however, long-term disease resolution is disappointing because of low rates of seroconversion and the development of drug-resistant viral mutants. 3 There is an urgent need for more effective antiviral therapies that can completely reduce or eliminate viral infection with fewer side effects. Although there is a wealth of information about the virus and the possible role that host factors may play in the infectious life cycle, 1,4-6 the direct relationship between chronically infected patients and host-pathogen interactions is poorly understood. DNA microarray technology has been used to measure the mRNA levels of thousands of cellular genes under a variety of experimental conditions. This approach is being used increasingly to monitor cellular gene expression in response to viral infection, expression of viral genes, or treatment with antiviral compounds such as interferon. [7] [8] [9] In this study, we performed genomic gene expression profiling in HepG2 cells and HepG2.2.15 cells using the Human Whole Genome Bioarray. HepG2.2.15 cells that are transfected with the HBV genome stably secrete hepatitis B virions and express all HBV proteins. The change in gene expression in HepG2.2.15 cells both before and after lamivudine treatment was also analyzed. Microarray data further suggested that a set of genes is involved in the cellular responses to HBV infection. Finally, we compared the anti-HBV activity of antisense oligodeoxynucleotides (ASODNs) against selected genes at both the DNA and the protein levels to validate our observations from the gene profiling experiments. Potential HBV response genes and novel targets for anti-HBV drugs were identified.
Results

Effect of lamivudine on HBV replication
HepG2.2.15 cells were used as a blank control. As shown in Figure 1 , 25 mM lamivudine significantly attenuated HBV replication but had little effect on hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) production in HepG2.2.15 cells 8 days post-infection.
Cytotoxicity of lamivudine
During lamivudine treatment, cell morphology was visualized each day using a microscope. No visible differences were observed between the morphology of the test and control cells. Cell counting results revealed no significant differences between them (P40.05, n ¼ 3). Thus, no visible cytotoxicity was observed in response to 25 mM lamivudine treatments in HepG2.2.15 and HepG2 cells.
Differentially expressed genes in the HepG2.2.15 and HepG2 cell lines To study genes that were differentially expressed between the HepG2.2.15 cell line and its parental cell line, HepG2, we used Amersham CodeLink Human Whole Genome Bioarray to systematically compare the gene expression profiles of both cell lines. We found that 2978 genes were up-or downregulated by at least twofold. Of these 2978 genes, 1358 genes had defined functional activities (Table 1) , whereas 1620 genes were new expressed sequence tags (ESTs) with unknown functions. Of the 1358 known genes, 759 were upregulated, whereas 599 genes were downregulated. Approximately half of these genes could be classified into functional categories, including signal transduction, transport, cell adhesion, cell cycle and cellular metabolism. with 2465 genes up-or downregulated by at least twofold. Of the 2465 differentially regulated genes, many more were overexpressed (71%) than underexpressed (29%) in the HepG2.2.15 cells after lamivudine treatment. Over half (52%) of the differentially expressed genes had functions that have not been characterized. The remaining 48% had numerous biologic functions as assessed by Gene Ontology (GO), including cellular metabolism, transport, signal transduction, cell cycle, cell adhesion, growth, apoptosis and immune responses (Table 1) .
Screening for potential HBV-infection-associated genes and possible targets for anti-HBV therapy The differential gene expression induced by HBV and lamivudine treatment was compared with the screening of important HBV-infection-associated genes. We found that 22 genes were upregulated in the HepG2.2.15 cells and downregulated by lamivudine (Table 2 ). These may be important HBV-infection-associated genes and potential targets for anti-HBV drugs.
Validation of the mRNA expression of selected genes To ensure the altered expression level, nine genes (KHDRBS3, EPC1, CDC34, ACVR2B, EREG, IGF2, TGFB1, RORA and ABHD2) were selected and tested using semiquantitative reverse transcription (RT)-PCR ( Figure 2 ). These genes were upregulated in HepG2. Whole genome expression profiling of hepatitis B virus-transfected cell line
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Thus, we selected ABHD2 and EREG as HBV-infectionassociated genes.
Discussion
Persistent HBV infection results from the interaction between HBV and host cells, and ultimately leads to the development of liver cirrhosis and HCC. 10 Because the interaction between HBV and host cells is involved in many cellular signaling pathways, it has not been completely defined. 1, [11] [12] [13] [14] Inhibiting such cellular processes would be expected to have an antiviral effect. Evidence for this extends across many diverse virus types, including poxviruses, 15 herpesviruses, [16] [17] [18] retroviruses, 19 hepadnaviruses 20, 21 and flaviviruses. 22 Moreover, any licensed drug that targets a human disease process affects the functioning of a cell or organ system in some way. Thus, in effect we have a readymade pharmacy of antiviral agents with defined safety data profiles.
Microarray technology has provided an opportunity to analyze complex viral-host interactions at the global level. Lamivudine has been a leading drug in the treatment of chronic HBV infection for the past decade. It is an orally administered nucleoside analog that is highly effective at inhibiting HBV DNA synthesis. Lamivudine selectively targets the HBV viral reverse transcriptase and directly blocks replication of the HBV genome. 24 In this study, lamivudine was used as a tool to inhibit the differential expression of genes induced by non-HBV infection factors. To screen for host-cell genes that are altered by HBV infection, changes in gene expression were studied in lamivudine-treated HepG2.2.15 cells. We obtained 22 functional genes that were upregulated in HBV-infected HepG2.2.15 cells and downregulated after lamivudine treatment. Many of the selected genes are well characterized and have widely varying functions as cell-cycle components, ligands, receptors, kinases, and signal transduction molecules, metabolism components, transcription regulators, and transport and development proteins. For example, HBx interacted with the ATF3 transcription factor to improve its expression. 25 HBx stimulation of IGF-II gene expression and autocrine IGF-II production involves phosphorylation and activation of the Sp1 transcription factor using the protein kinase C and p44/p42 mitogen-activated kinase pathways, and increased IGF-II gene expression may be involved in HBV-associated chronic liver disease pathogenesis. 26, 27 HBx also enhanced transforming growth factorb1 (TGFb1) expression. 28 HBxAg promotes TGFb1 activity by upregulating TGFb1 and downregulating a2-macroglobulin. 29 A relationship between the remaining genes and HBV infection has not yet been reported.
We also validated the differential expression of 9 of the 22 genes (ABHD2, EREG, ACVR2B, CDC34, KHDRBS3, RORA, EPC1, TGFB1 and IGF2) using semiquantitative RT-PCR. All of these genes were upregulated by HBV and downregulated after lamivudine treatment of HepG2.2.15 cells.
Persistent HBV infection is shown to impact host-cell pathways and enzymes. Excluding genes that were previously reported to share a close relationship with HBV, we discovered that ABHD2, EREG, ACVR2B, CDC34, KHDRBS3 and RORA also shared a strong relationship with HBV virus infection and could be critical for supporting the propagation of HBV-infected hepatic cells. These proteins may serve as potential targets for anti-HBV drugs.
Viruses generally use host-cell enzymes for replication, including those with hydratase catalytic activity. Carboxypeptidase N, a plasma metalloprotease, can bind, and activated core promoter of HBV. 30 Moreover, the cellular enzyme, S-adenosyl-L-homocysteine hydrolase, plays an important regulatory role in S-adenosyl-L-methioninedependent methylation reactions. 31 S-adenosyl-L-homocysteine hydrolase inhibition has an antiviral effect because most plant and animal viruses require a methylated cap structure at the 5 0 terminus of their mRNA in order for viral replication to occur. 32 Thus, by inhibiting S-adenosyl-Lhomocysteine hydrolase, the virus-encoded methyltransferases involved in the formation of this methylated cap structure are inhibited and viral replication is slowed. ABHD2, a a/b hydrolase protein family member, has strong hydratase catalytic activity. 33 We speculate, therefore, that ABHD2 may participate in HBV replication. On the other hand, EREG is a member of epidermal growth factor family and is able to enhance STAT1 activity, increasing p21WAF1/ CIP1 expression, and stagnating cells in the G1 stage. 34 Numerous investigations have indicated that both DHBV 35, 36 and HBV replicate more efficiently in quiescent cells 37, 38 than proliferating cells. Thus, we would speculate that by inhibiting EREG expression, cells would proliferate from the metabolic stage.
A reduction in gene expression may decrease HBV replication. To support our speculation, antiviral activity of selected genes was validated using ASODN technology. ASODNs are based on the complementarity of the constructs to the appropriate target mRNA. Several mechanisms of action exist that lead to antisense effects, such as the inhibition of transcription, modulation of RNA processing, inhibition of translation, and selective cleavage of the target mRNA using the cellular endonuclease, RNaseH. 39 We initially screened potential anti-HBV targets by ASODNs against the above six genes to inhibit gene expression and observe the antiviral effects against HBV. Downregulation of ABHD2 and EREG by ASODNs significantly inhibited HBV propagation, whereas downregulation of ACVR2B, CDC34, KHDRBS3 or RORA had a reduced effect on HBV propagation. Thus, ABHD2 and EREG are likely to be essential for HBV propagation, such that inhibited expression reduces HBV levels.
In summary, by utilizing the Human Whole Genome Bioarray, we performed a global analysis of gene expression induced by HBV and lamivudine. As a result, we identified 22 important HBV infection-related genes. We validated nine genes, including IGF2, TGFB1, EPC1, ABHD2, ACVR2B, CDC34, EREG, KHDRBS3 and RORA using RT-PCR technology. ASODNs targeting ABHD2 and EREG significantly inhibited HBV propagation, respectively. Thus, we would conclude that ABHD2 and EREG are essential for HBV propagation and may serve as potential targets for anti-HBV drugs.
Materials and methods
Compounds
Lamivudine was abstracted from the lamivudine tablets and was dissolved in phosphate-buffered saline with the concentration of 1 mM.
Cell culture The HepG2.2.15 cells (clonal cells derived from HepG2 cells that were transfected with a plasmid containing HBV DNA), which secrete hepatitis B virions, 40, 41 were kindly provided by the Beijing Medical University and was originally from the Mount Sinai Medical Center (New York, NY, USA). HepG2.2.15 cells and HepG2 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal bovine serum, at 371C, 5% CO 2 . 380 g/ml G418 was needed in HepG2. 
RNA isolation and target preparation
Total RNA from HepG2 cells, HepG2.2.15 cells and HepG2.2.15 cells treated by lamivudine at 8-day point were extracted using Trizol total RNA extraction Kit (Invitrogen, Carlsbad, CA, USA) as the manufacturer's instructions, followed by purification using RNeasy Mini columns (Qiagen Inc., Valencia, CA, USA). The products were quality-controlled on formaldehyde agarose gels. The concentration was examined by using nuclear acid and protein analyzer (DU640, Beckman, Fullerton, CA, USA). Doublestranded cDNA and subsequent cRNA was synthesized from 2 mg of total RNA using the CodeLink Expression Assay Kit (Amersham Biosciences, Chandler, AZ, USA) according to manufacturer's instructions. Briefly, cRNA was prepared by in vitro transcription (IVT) using a single, labeled nucleotide, biotin-11-UTP in the IVT reaction at a concentration of 1.875 mM. Unlabeled UTP was present at 5.625 mM, whereas GTP, ATP and CTP were at 7.5 mM. cRNA was synthesized at 371C overnight for 14 h, and the target product was recovered by RNeasy MiNi Kit (Qiagen Inc.) and quantified with an UV spectrophotometer.
Arrays hybridization and image processing
A 20 mg of target cRNA was fragmented in 1 Â fragmentation buffer (40 mM Tris-acetate (pH 7.9), 100 mM KOAc and 31.5 mM MgOAc) at 941C for 20 min. For hybridization with CodeLink bioarrays (Amersham Biosciences), 20 mg of fragmented cRNA in 260 ml of hybridization solution was injected into each hybridization chamber of a CodeLink Human Whole Genome Bioarray, which targets B57 000 transcripts and ESTs, including B45 000 well-characterized human gene and transcript targets based on the NCBI/ UniGene database (Amersham Biosciences). The slides were incubated at 371C for 22 h with shaking, The four bioarrays, in this study, were processed in parallel using the CodeLink Shaker Kit and CodeLink Parallel Processing Kit (Amersham Biosciences). Bioarrays were stained with Cy5t-streptavadin (Amersham Biosciences) and scanned using a GenePix 4000B scanner (Axon Instruments, Union City, CA, USA). The scanned image files were analyzed using CodeLink Scanning and Expression Analysis software (version 2.3; Amersham Biosciences), which produced both raw and normalized hybridization signal intensities for each spot on the arrays.
Analysis of mRNA expression by semiquantitive RT-PCR
RT-PCR quantification was used to verify the microarray data. The cDNA templates were synthesized from 2 mg total RNA, using SuperScript II reverse transcriptase (Invitrogen) and oligo(dT) primer. PCR was performed in a single reaction of 20 ml volume. The schedule consisted of incubation for 5 min at 941C followed by 20-30 cycles of 941C for 20 s, 551C for 20 s and 721C for 20 s, then incubation for 5 min at 721C. The PCR products were analyzed by running the reaction products on 2% agarose/ethidium bromide gels. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was used as inner standard. The primers for each gene validated by RT-PCR are shown in Table 3 .
ASODNs design and synthesis
The whole-length mRNA sequence of ABHD2 (GeneBank no.: NM_007011), EREG (GeneBank no.: NM_001432), ACVR2B (GeneBank no.: NM_001106), CDC34 (GeneBank no.: NM_004359), KHDRBS3 (GeneBank no.: NM_006558) and RORA (GeneBank no.: NM_134261) were chosen as target sequence. Using IDT SciTools web server (http:// www.idtdna.com/Scitools/Applications/AntiSense/Antisense. aspx), one region with local structures motifs, which have been presented to be favorable for the invasion of ASODN, was chosen as target site. Blast confirmed that ASODN was specific for corresponding gene above (Table 4 ). All ASODNs were synthesized at ABI8909 nucleic acid synthesis system (Applied Biosystems, Foster City, CA, USA) and purified by OPC (Perkin-Elmer, Foster City, CA, USA). Considering that phosphorothiate ASODNs are very resistant to nucleases, 43, 44 all these ASODNs had been chemically modified to phosphorithioate ODNs by substituting the oxygen molecules of the phosphate backbone with sulfur. . Transfections were carried out 3 days after plating by using lipofectin transfection reagent (8 mg/ml lipofectin for 0.8 mmol/l oligos; Invitrogen) as instructed by the manufacturer. After incubation of oligos with cells for 6 h, the media was replaced and cultures were incubated for 72 h before analysis of mRNA and protein levels, HBV DNA, HBsAg and HBeAg levels.
Detecting HBV DNA in cell medium by real-time PCR To assess HBV DNA levels, HBV DNA copies in culture medium were determined by real-time PCR. Cell mediums were incubated at 941C for 15 min. After centrifugation at 12 000 r.p.m. for 10 min, the supernatants were used as the template for real-time PCR. The real-time PCR were performed as described previously. 45, 46 The forward primer of HBV DNA is 5 0 -GGA GTATGGATTCGCACTCCTC-3 0 , the reverse primer is 5 0 -TTGTTGTTGTAGGGGACCTGCCT-3 0 , the fluorescent probe is 5 0 -ACTTCCGGAAACTACTGTTAGACGA-3 0 , and the quenching probe is 5 0 -GTAGTTTCCGGAAGT-3 0 . PCR amplification and analysis were performed using iCycler real-time PCR detector (Bio-Rad, Hercules, CA, USA). Assays were repeated in triplicate and average threshold cycle values were used to determine the concentration of HBV DNA. The inhibition rate was calculated as the following formula: IR (%) ¼ (C control ÀC tester )/C control Â 100%. C control represents HBV DNA copies in HepG2.2.15 cells, which were normalized by cell number; C tester represents HBV DNA copies in treated cells, which were normalized by cell number.
Cytotoxicity
Cell morphologic character was monitored everyday after lamivudine's treatment in the microscope. After HepG2.2.15 cells were grown in the presence of lamivudine for 8 days, the cell number was determined by using hemacytometer. 
Statistical analysis
The data were expressed as means7s.d., statistical analysis was performed by Student's t-test (two-tailed) and one-way ANOVA.
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